The Mount Sinai Tisch Cancer Center has introduced a groundbreaking AI platform, PRISM, designed to connect cancer patients with relevant clinical trials. With 1 in 5 individuals expected to face cancer in their lifetime, participation in clinical trials remains alarmingly low at around 7% due to barriers such as lack of awareness and logistical challenges. PRISM harnesses an AI-powered framework developed by Triomics, streamlining the identification process by reviewing electronic medical records to pinpoint eligible patients efficiently. This innovation aims to boost clinical trial enrollment, enhance access to cutting-edge therapies, and improve treatment outcomes while reducing the burden on clinical research staff. According to Karyn Goodman, MD, the platform not only optimizes patient matching but also promotes diversity and equity in clinical trial participation. By utilizing advanced AI tools, the TCC aspires to eliminate barriers, ensuring more patients benefit from vital cancer research initiatives. Share this insight on Pinterest to spread awareness of this innovative approach.
Source link
